Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300395 | 0.96 | MAPT (0.55) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL3085908 | 0.86 | MAPT (0.57) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL3300398 | 0.84 | MAPT (0.54) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL2951095 | 0.84 | KIT (0.71) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL2946622 | 0.81 | BTK (0.67) | CYP2C9BRAFEIF2AK3EIF2AK4 | |
| SCHEMBL3302139 | 0.81 | KCNQ3 (0.55) | MAPTMEN1HTTKMT2ATP53 | |
| SCHEMBL10092719 | 0.81 | MAPT (0.59) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL17664661 | 0.80 | MAPT (0.61) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL4251497 | 0.80 | BRAF (0.68) | MAPTCYP2C9BRAFLMNAGAA | |
| SCHEMBL5494349 | 0.78 | MAPT (0.65) | MAPTMEN1HTTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795273-B2 | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | claimed |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | HOLZER PHILIPP | 2010-04-15 | — | — | US | claimed |
| EP-2079702-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| US-20080300245-A1 | Pyrazolo[1,5-A]Pyridine-3-Carboxylic Acids as Ephb and Vegfr2 Kinase Inhibitors | IMBACH PATRICIA | 2008-12-04 | — | — | US | claimed |
| EP-1963316-A2 | PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACIDS AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2008052974-A1 | 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | claimed |
| WO-2007065664-A2 | PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACIDS AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | claimed |
| US-7795273-B2 | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | HOLZER PHILIPP | 2010-04-15 | — | — | US | disclosed |
| US-20080300245-A1 | Pyrazolo[1,5-A]Pyridine-3-Carboxylic Acids as Ephb and Vegfr2 Kinase Inhibitors | IMBACH PATRICIA | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300245-A1 | Pyrazolo[1,5-A]Pyridine-3-Carboxylic Acids as Ephb and Vegfr2 Kinase Inhibitors | EPHB2, EPHB1, EPHB3 | MAPT 1687/4885MEN1 3755/4885HTT 4803/4885 |
| US-20100093821-A1 | 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases | MAP4K2, MAP4K3, MAP4K1 | MAPT 1799/4885MEN1 3441/4885HTT 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.